Evidence map›Paper›PMID 29234152›Full record

ArticleCancer gene therapy2018

LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer.

Haoyu Zhou, Zhihua Sun, Songwei Li, Xiaofeng Wang, Xuejun Zhou

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.International journal of molecular sciences · 2019
    Review
  14. Long Non-Coding RNA ZFAS1 as a Novel Potential Biomarker for Predicting the Prognosis of Thyroid Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Haoyu ZhouSchool of Food Science, Henan Institute of Science and Technology, Xinxiang, Henan Province, 453000, China.
Zhihua SunInstitute of Tropical Agriculture and Forestry, Hainan University, Haikou, Hainan Province, 570228, China.
Songwei LiSchool of resources and environment, Henan Institute of Science and Technology, Xinxiang, Henan Province, 453000, China.
Xiaofeng WangENT & HN Surgery Department, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, 570102, China. xiaofengwang5151@163.com.
Xuejun ZhouENT & HN Surgery Department, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, 570102, China. haijunzhou1120@163.com.
Hainan Medical University · CNHenan Institute of Science and Technology · CNHainan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have been demonstrated to be critical regulators in tumorigenesis. LncRNA SPRY4-IT1 has been identified as critical regulator for hepatocellular carcinoma and ovarian cancer. However, the potential role and clinical value of SPRY4-IT1 in human thyroid cancer (TC) still remain unclear and need to be uncovered. Our current study was aimed to ascertain the biological role of expression of SPRY4-IT1 in TC tissues and cells. Our findings revealed that the level of SPRY4-IT1 was significantly upregulated in TC tissues and cell lines, which was correlated with poor prognosis. And cellular experiments exhibited that silenced SPRY4-IT1 inhibited the proliferative and migratory abilities of TC cells. Mechanism assays noted that silenced SPRY4-IT1 could increase the levels of transforming growth factor-β1 (TGF-β1) and p-Smad2/3 and function mediated by si-SPRY4-IT1 could be rescued by the interference of TGF-β1. Generally speaking, these findings elucidated that SPRY4-IT1 might become a novel prognostic factor in the clinical behaviors of TC patients and participated in the progression of TC through targeting TGF-β/Smad signaling pathway.

Indexed as

Gene Expression RegulationUp-RegulationAdultCell Line, TumorCell MovementCell ProliferationFemaleHumansMaleMiddle AgedPrognosisRNA, Long NoncodingRNA, NeoplasmThyroid Neoplasmslong noncoding RNA SPRY4-IT1, humanRNA, Long NoncodingRNA, Neoplasm

Identifiers

PMID29234152
OpenAlexW2772846934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.